GBT
CRL icon

Grove Bank & Trust’s Charles River Laboratories CRL Stock Holding History

Grove Bank & Trust’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.01K Hold
17
– – ﹤0.01% 736
2026
Q2 		$3.85K Hold
17
– – ﹤0.01% 756
2026
Q1 		$2.93K Buy
17
+16
+1,600% +$2.97K ﹤0.01% 759
2025
Q4 		$199 Hold
1
– – ﹤0.01% 847
2025
Q3 		$156 Hold
1
– – ﹤0.01% 825
2025
Q2 		$152 Sell
1
-19
-95% -$2.53K ﹤0.01% 848
2025
Q1 		$3.01K Buy
20
+12
+150% +$2.01K ﹤0.01% 739
2024
Q4 		$1.48K Buy
8
+1
+14% +$193 ﹤0.01% 706
2024
Q3 		$1.38K Buy
+7
New +$1.46K ﹤0.01% 692
2022
Q1 		– Sell
-680
Closed -$256K – 231
2021
Q4 		$256K Hold
680
– – 0.05% 204
2021
Q3 		$281K Hold
680
– – 0.06% 194
2021
Q2 		$252K Buy
+680
New +$227K 0.05% 192
2018
Q1 		– Sell
-680
Closed -$74K – 230
2017
Q4 		$74K Hold
680
– – 0.03% 255
2017
Q3 		$73K Buy
680
+100
+17% +$10.3K 0.04% 257
2017
Q2 		$59K Buy
580
+90
+18% +$8.28K 0.04% 235
2017
Q1 		$44K Hold
490
– – 0.04% 227
2016
Q4 		$37K Buy
+490
New +$37.2K 0.03% 261

Other funds holding CRL

CIM
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Grove Bank & Trust's CRL Position: Q3 2026 in Review

Grove Bank & Trust held its Charles River Laboratories (CRL) position steady in Q3 2026 at 17 shares worth $5.01K. The position accounts for ﹤0.01% of the portfolio, ranked #736.

Grove Bank & Trust first reported a position in CRL in Q4 2016 and has held it in 17 quarters since. The position peaked at $281K in Q3 2021. 15 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Grove Bank & Trust held 17 shares of Charles River Laboratories worth $5.01K as of Q3 2026.
  • Grove Bank & Trust left its Charles River Laboratories share count unchanged in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Grove Bank & Trust's portfolio in Q3 2026, its #736 holding.
  • Grove Bank & Trust first reported a position in Charles River Laboratories in Q4 2016 and has held it in 17 quarters since.
  • Grove Bank & Trust's Charles River Laboratories position peaked at $281K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Grove Bank & Trust's 13F filing for Q3 2026, filed 8 Oct 2026.